SG
DFTX

Sankala Group’s Definium Therapeutics DFTX Stock Holding History

Sankala Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.56K Sell
141
-250
-64% -$4.24K ﹤0.01% 475
2025
Q4 		$6.82K Buy
+391
New +$4.84K 0.01% 427

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sankala Group's DFTX Position: Q1 2026 in Review

Sankala Group reduced its Definium Therapeutics (DFTX) stake by 64% in Q1 2026, selling an estimated $4.24K and leaving 141 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

Sankala Group first reported a position in DFTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $6.82K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Sankala Group held 141 shares of Definium Therapeutics worth $2.56K as of Q1 2026.
  • Sankala Group sold 250 Definium Therapeutics shares in Q1 2026, an estimated $4.24K.
  • Definium Therapeutics made up ﹤0.01% of Sankala Group's portfolio in Q1 2026, its #475 holding.
  • Sankala Group first reported a position in Definium Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Definium Therapeutics position peaked at $6.82K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.